

Resource Summary Report

Generated by [NIF](#) on Sep 1, 2026

New York University School of Medicine Center for Biospecimen Research and Development Histology Core Facility

RRID:SCR_018304

Type: Tool

Proper Citation

New York University School of Medicine Center for Biospecimen Research and Development Histology Core Facility (RRID:SCR_018304)

Resource Information

URL: <https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development>

Proper Citation: New York University School of Medicine Center for Biospecimen Research and Development Histology Core Facility (RRID:SCR_018304)

Description: Assists researchers and clinicians with molecular and morphologic characterization of normal and disease tissues of interest in support of biomarker discovery and translational research. Offers both routine and advanced histology immunohistochemistry, in situ and whole slide scanning services.

Synonyms: NYU Grossman School of Medicine Center for Biospecimen Research and Development Histology, NYU Langone Center for Biospecimen Research and Development

Resource Type: access service resource, core facility, service resource

Keywords: Morphologic characterization, tissue, biomarker discovery, histology, immunochemistry, whole slide scanning, ABRF, ABRF

Availability: Restricted

Resource Name: New York University School of Medicine Center for Biospecimen Research and Development Histology Core Facility

Resource ID: SCR_018304

Alternate IDs: ABRF_672

Alternate URLs: <https://coremarketplace.org/?FacilityID=672>

Record Creation Time: 20220129T080339+0000

Record Last Update: 20260829T183304+0000

Ratings and Alerts

No rating or validation information has been found for New York University School of Medicine Center for Biospecimen Research and Development Histology Core Facility.

No alerts have been found for New York University School of Medicine Center for Biospecimen Research and Development Histology Core Facility.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 46 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#).

Pillai R, et al. (2026) LIF-Induced Tumor Plasticity Establishes an Immunosuppressive Myeloid Niche in LKB1-Mutant Lung Cancer. *Cancer discovery*, 16(7), 1436.

Bossowski JP, et al. (2026) The integrated stress response promotes immune evasion through lipocalin 2. *Nature*, 652(8112), 1329.

Li C, et al. (2026) Choroid plexus and perivascular space abnormalities in CerTra syndrome: neuroimaging and histological findings. *Frontiers in neurology*, 17, 1792598.

You J, et al. (2026) Optimization and comparison of genomic DNA extraction from whole blood collected in PAXgene blood RNA tube using automated platforms. *Clinical chemistry and laboratory medicine*, 64(3), 600.

Schmauch E, et al. (2026) Multi-omics analysis of a pig-to-human decedent kidney xenotransplant. *Nature*, 650(8100), 205.

Jaffe IS, et al. (2025) Unused Samples from Clinical Blood Draws as a Resource for Maximizing Research Samples while Mitigating Iatrogenic Anemia Risks: A Pilot Study. *medRxiv : the preprint server for health sciences*.

Novikova E, et al. (2025) Coordinated circulating and tissue-based T cell responses precede xenograft rejection. *bioRxiv : the preprint server for biology*.

Azeem SM, et al. (2025) EGR1 Mediates Riluzole-Induced Apoptosis in Osteosarcoma via the Yap/p73-Bax Signaling Axis. *bioRxiv : the preprint server for biology*.

Coudray N, et al. (2025) Self supervised artificial intelligence predicts poor outcome from primary cutaneous squamous cell carcinoma at diagnosis. *NPJ digital medicine*, 8(1), 105.

Fa'ak F, et al. (2025) Artificial Intelligence Algorithm Predicts Response to Immune Checkpoint Inhibitors. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(16), 3526.

Martá-Ariza M, et al. (2025) Comparison of the amyloid plaque proteome in Down syndrome, early-onset Alzheimer's disease, and late-onset Alzheimer's disease. *Acta neuropathologica*, 149(1), 9.

Karatza A, et al. (2025) Cross-species analysis identifies genotype-driven vulnerabilities in lung adenocarcinoma. *bioRxiv : the preprint server for biology*.

Barcia Durán JG, et al. (2024) Immune checkpoint landscape of human atherosclerosis and influence of cardiometabolic factors. *Nature cardiovascular research*, 3(12), 1482.

Martá-Ariza M, et al. (2024) Comparison of the Amyloid Plaque Proteome in Down Syndrome, Early-Onset Alzheimer's Disease and Late-Onset Alzheimer's Disease. *Research square*.

Claudio Quiros A, et al. (2024) Mapping the landscape of histomorphological cancer phenotypes using self-supervised learning on unannotated pathology slides. *Nature communications*, 15(1), 4596.

Wise DR, et al. (2024) A Phase 1/2 multicenter trial of DKN-01 as monotherapy or in combination with docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC). *Prostate cancer and prostatic diseases*.

Lin LH, et al. (2024) Increased PI3K pathway activity is associated with recurrent breast cancer in patients with low and intermediate 21-gene recurrence score. *Journal of clinical pathology*.

Coudray N, et al. (2024) Quantitative and Morphology-Based Deep Convolutional Neural Network Approaches for Osteosarcoma Survival Prediction in the Neoadjuvant and Metastatic Setting. *Clinical cancer research : an official journal of the American Association for Cancer Research*.

Schmauch E, et al. (2024) Integrative multi-omics profiling in human decedents receiving pig heart xenografts. *Nature medicine*, 30(5), 1448.

Berger S, et al. (2024) Preclinical proof of principle for orally delivered Th17 antagonist miniproteins. *Cell*, 187(16), 4305.